☆ 4.6 Letter

Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis

BRITISH JOURNAL OF DERMATOLOGY (2016)

Journal

BRITISH JOURNAL OF DERMATOLOGY

Volume 174, Issue 1, Pages 201-203

Publisher

WILEY

DOI: 10.1111/bjd.13961

Keywords

-

Categories

Dermatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Dermatology

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

L. M. Prens, K. Bouwman, P. Aarts, S. Arends, K. R. van Straalen, K. Dudink, B. Horvath, E. P. Prens

Summary: This study evaluated the drug survival of antitumour necrosis factor biologics for patients with hidradenitis suppurativa in daily practice. Survival rates for adalimumab and infliximab were similar at 12 months, mainly determined by ineffectiveness. Age, disease duration (adalimumab), and surgery (infliximab) were identified as predictors for longer drug survival.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Review Dermatology

Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: A PRISMA-compliant meta-analysis of data from daily practice

Qiaohong Wang, Liheng Chen

Summary: Fifteen eligible studies on methotrexate therapy of moderate-to-severe atopic dermatitis were identified through electronic searches. The response rates for short-term and medium/long-term therapy were 77% and 88.9% respectively, with children having a lower treatment discontinuation rate but more frequent side effects.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Use of Systemic Medications for Treating Adult Atopic Dermatitis in France: Results of a Practice Survey

Anne-Claire Fougerousse, Caroline Jacobzone, Laure Mery-Bossard, Ziad Reguiai, Catherine Droitcourt, Charles Taieb, Francois Maccari

Summary: Recent studies show that systemic medications are underused for treating adult AD, with concerns regarding the safety of cyclosporine. Dermatologists often do not perform evaluation scoring before initiating systemic treatment for adult AD, and a majority of them do not prescribe cyclosporine or methotrexate due to reasons such as lack of eligible patients, information, experience, or approval in France.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Brandon I. Smith, Priya Engel, Jashin Wu

Summary: The authors conclude that lebrikizumab therapy is safe and effective for moderate-to-severe atopic dermatitis in adolescents and adults based on two phase 3 trials. However, they note the lack of racial diversity in the trials, with majority of the patients being White.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Dermatology

Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study

Niccolo Gori, Alvise Sernicola, Ersilia Tolino, Maria Mariano, Marco Galluzzo, Gaia Moretta, Rosa Coppola, Andrea D'Alessio, Massimo Sansone, Virginia Maffei, Claudia Paolino, Cristian Ferrao, Lauro Cascia, Paola Addio, Lucia Di Nardo, Andrea Chiricozzi, Ester Del Duca, Antonio Cristaudo, Luca Bianchi, Sabatino Pallotta, Vincenzo Panasiti, Giovanni Pellacani, Concetta Potenza, Ketty Peris

Summary: This study analyzed the drug survival rate of dupilumab up to 2 years in adult patients with moderate/severe atopic dermatitis, and investigated the factors influencing treatment persistence. The study found that the drug survival rate at 12 and 24 months was 88.6% and 76.1% respectively. Factors such as adult onset of AD and severity of EASI score at the last follow-up visit were significantly associated with lower drug survival.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Add to Collection

Article Dermatology

Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry

Henrik H. P. Larsen, Ida Vittrup, Iben F. Ruge, Jesper Elberling, Lone Skov, Kristina Ibler, Gregor B. E. Jemec, Charlotte G. Mortz, Rasmus O. Bach, Carsten Bindslev-Jensen, Maiken Dalager, Tove Agner, Mette Deleuran, Christian Vestergaard, Jacob P. Thyssen

Summary: This study describes the baseline characteristics of adult patients with moderate-to-severe atopic dermatitis enrolled in the Danish nationwide SCRATCH database. The findings provide a source of data for future efficacy and safety studies.

ACTA DERMATO-VENEREOLOGICA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Unique Gut Microbiome Signatures among Adult Patients with Moderate to Severe Atopic Dermatitis in Southern Chinese

Yiwei Wang, Jinpao Hou, Joseph Chi-Ching Tsui, Lin Wang, Junwei Zhou, Un Kei Chan, Claudia Jun Yi Lo, Pui Ling Kella Siu, Steven King Fan Loo, Stephen Kwok Wing Tsui

Summary: The study found that there are differences in the gut microbiome structure and metabolic functions between adult atopic dermatitis (AD) patients and healthy individuals. AD patients are more prone to allergies, especially non-food allergies. Additionally, the gut microbiome composition differs significantly between the AD and normal groups. The study also suggests potential therapeutic strategies targeting the gut microbiome for AD and provides evidence for the involvement of the gut-skin axis in AD patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Dermatology

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F. M. Ariens, Jorien van der Schaft, Lotte S. Spekhorst, Daphne S. Bakker, Geertruida L. E. Romeijn, Tessa A. Kouwenhoven, Marijke Kamsteeg, Angelique N. Voorberg, Albert J. Oosting, Ilona de Ridder, Annemieke Sloeserwij, Inge Haeck, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein S. De Bruin-Weller

Summary: This study aimed to investigate the long-term effectiveness and safety of dupilumab in patients with treatment-refractory atopic dermatitis. The results showed a continuous improvement in clinical outcome measures during the 52-week follow-up period, with some patients experiencing adverse reactions, suggesting caution in the use of dupilumab.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Andac Salman, Ozlem Apti Sengun, Meryem Aktas, Oktay Taskapan

Summary: The study found high effectiveness and safety of dupilumab in treating moderate-to-severe AD in real-life conditions, with most patients continuing treatment during the COVID-19 pandemic without adverse outcomes. Although the rate of conjunctivitis was higher than in clinical trials, no patients discontinued treatment due to adverse effects.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice

Anne R. Schloesser, Madena Shareef, Jill Olydam, Tamar E. C. Nijsten, Dirk Jan Hijnen

Summary: Tralokinumab was found effective in most patients with severe atopic dermatitis in daily practice. It was also effective in 50% of patients who had previously experienced insufficient response or adverse events with Dupilumab.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis

Martina Maurelli, Paolo Gisondi, Francesco Bellinato, Alessandro Mantovani, Giovanni Targher, Giampiero Girolomoni

Summary: This study investigated the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with moderate-to-severe atopic dermatitis (AD), and found that the prevalence of NAFLD in AD patients was comparable to that in patients with a previous diagnosis of in situ melanoma. The results suggest that the Th2-type inflammation characteristic of AD is not a risk factor for NAFLD. Therefore, it is recommended to screen patients with moderate-to-severe psoriasis, but not those with AD, for NAFLD and other metabolic comorbidities.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Pharmacology & Pharmacy

Topical tacrolimus during systemic therapy for severe atopic dermatitis in the clinical practice

S. M. Ferrucci, L. Angileri, A. Marzano, E. Berti, S. Tavecchio

Summary: This study evaluated the role of tacrolimus ointment in patients with severe atopic dermatitis receiving dupilumab therapy. The results suggest that early treatment with tacrolimus in localized areas can improve the efficacy of systemic treatment.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study

Chin-Yi Yang, Po-Ju Lai, Chun-Bing Chen, Tom C. Chan, Rosaline Chung-Yee Hui, Yu-Huei Huang, Han-Chi Tseng, Shang-Hung Lin, Chun-Wei Lu, Hua-En Lee, Jing-Yi Lin, Min-Hui Chi, Ming-Feng Tsai, Yih-Shiou Hwang, Chuang-Wei Wang, Chia-Yu Chu, Wen-Hung Chung

Summary: This study investigates the response to dupilumab treatment in adult patients with atopic dermatitis, finding that phenotype-related characteristics are associated with treatment efficacy. It suggests that treatment should not be discontinued until a satisfactory clinical response is achieved.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Allergy

Transcriptome-based identification of novel endotypes in adult atopic dermatitis

Alain Lefevre-Utile, Melissa Saichi, Peter Olah, Marc Delord, Bernhard Homey, Vassili Soumelis

Summary: The study identified 4 endotypes of AD and discovered key gene sets associated with specific biological pathways. There were significant differences in disease severity and S. aureus colonization between different clusters. These findings could potentially provide new insights into personalized treatment strategies.

ALLERGY (2022)

Add to Collection

Article Medicine, General & Internal

Treatment with Methotrexate in Infants and Toddlers with Atopic Dermatitis: A Retrospective Multi-Center Study

Jen A. Barak Levitt, Sima Alemi, Ayelet Ollech, Shiran Reiss-Huss, Mohammad Sah, Yael Renert-Yuval, Rivka Friedland, Shoshana Greenberger, Eran Cohen Barak

Summary: This study investigated the efficacy and safety of methotrexate treatment in 28 infants and toddlers under the age of 4 with atopic dermatitis. After treatment, 50% of patients showed significant improvement at 12 weeks, and 21.4% achieved remission at 24 weeks. Although 57.1% of patients experienced adverse events, only two patients discontinued the treatment due to these events.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Allergy

Hand eczema and lifestyle factors in the Dutch general population: Evidence for smoking, chronic stress, and obesity

Laura Loman, Marie L. A. Schuttelaar

Summary: This study investigated the possible association between hand eczema (HE) and lifestyle factors, including smoking, alcohol consumption, stress, body mass index (BMI), waist circumference, physical activity, diet, and amount of sleep in the Dutch general population. The results indicated that smoking, chronic stress, high BMI, and large waist circumference were positively associated with HE in the past year. Further research should focus on the relationship between lifestyle factors and the severity and prognosis of HE.

CONTACT DERMATITIS (2022)

Add to Collection

Editorial Material Allergy

Baricitinib treatment of severe chronic hand eczema: Two case reports

Fieke M. Rosenberg, Laura Loman, Marie L. A. Schuttelaar

CONTACT DERMATITIS (2022)

Add to Collection

Article Allergy

Guidelines for diagnosis, prevention, and treatment of hand eczema

Jacob P. Thyssen, Marie L. A. Schuttelaar, Jose H. Alfonso, Klaus E. Andersen, Irena Angelova-Fischer, Bernd W. M. Arents, Andrea Bauer, Richard Brans, Alicia Cannavo, Wianda A. Christoffers, Marie-Noelle Crepy, Peter Elsner, Manige Fartasch, Francesca Larese Filon, Ana M. Gimenez-Arnau, Margarida Goncalo, Maria G. Guzman-Perera, Carsten R. Hamann, Wolfram Hoetzenecker, Jeanne Duus Johansen, Swen M. John, Amalia C. M. Kunkeler, Suzana Ljubojevic Hadzavdic, Sonja Molin, Rosemary Nixon, Jart A. F. Oosterhaven, Thomas Rustemeyer, Esther Serra-Baldrich, Mili Shah, Dagmar Simon, Christoph Skudlik, Radoslaw Spiewak, Skaidra Valiukeviciene, Angelique N. Voorberg, Elke Weisshaar, Tove Agner

Summary: Hand eczema is a common inflammatory skin disorder. This article aims to update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment of hand eczema. Consensus was reached for several statements and management strategies through analysis of evidence for therapeutic and preventive interventions using a structured method of developing consensus. The updated guideline should improve the management of hand eczema.

CONTACT DERMATITIS (2022)

Add to Collection

Editorial Material Dermatology

A new avenue for treatment of chronic hand eczema COMMENT

Marie L. A. Schuttelaar

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Association between moderate to severe atopic dermatitis and lifestyle factors in the Dutch general population

Junfen Zhang, Laura Loman, Marja Oldhoff, Marie L. A. Schuttelaar

Summary: This cross-sectional study conducted in the Netherlands explored the association between moderate to severe atopic dermatitis (AD) and lifestyle factors. The results showed that smoking, alcohol consumption, chronic stress, obesity, and sleep disturbances were associated with moderate to severe AD. These findings suggest the importance of screening and counseling for lifestyle factors in patients with moderate to severe AD.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Editorial Material Allergy

Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial

Angelique N. Voorberg, Esme Kamphuis, Wietske A. Christoffers, Geertruida L. E. Romeijn, Jart A. F. Oosterhaven, Marie L. A. Schuttelaar

CONTACT DERMATITIS (2022)

Add to Collection

Article Allergy

The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry

Angelique N. Voorberg, Geertruida L. E. Romeijn, Marjolein S. de Bruin-Weller, Marie L. A. Schuttelaar

Summary: This study suggests that Dupilumab may be a suitable treatment option for isolated CHE, with long-term therapeutic effects on HE patients.

CONTACT DERMATITIS (2022)

Add to Collection

Review Allergy

Lifestyle factors and hand eczema: A systematic review and meta-analysis of observational studies

Laura Loman, Marjolein J. Brands, Anna A. L. Massella Patsea, Klaziena Politiek, Bernd W. M. Arents, Marie L. A. Schuttelaar

Summary: Currently, there is limited evidence regarding the association between lifestyle factors and hand eczema, primarily due to heterogeneity and a limited number of studies.

CONTACT DERMATITIS (2022)

Add to Collection

Editorial Material Dermatology

Water and adult eczema: the hard truth?

Junfen Zhang, Marie L. A. Schuttelaar

Summary: This is an invited commentary letter discussing the association between domestic hard water and eczema in adults from the UK Biobank cohort study, published in the recent issue of BJD.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Allergy

Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry

Esme Kamphuis, Laura Loman, Henry L. Han, Geertruida L. E. Romeijn, Klaziena Politiek, Marie L. A. Schuttelaar

Summary: This prospective observational cohort study evaluated the effectiveness and safety of upadacitinib on atopic dermatitis (AD) and hand eczema (HE) in patients with AD. The results showed that upadacitinib can be an effective treatment for AD and concomitant HE. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non-atopic individuals.

CONTACT DERMATITIS (2023)

Add to Collection

Article Allergy

Limited Health Literacy and Its Associated Health Outcomes Among Adults With at Least 2 Atopic Diseases

Junfen Zhang, Laura Loman, Marie L. A. Schuttelaar

Summary: This study aimed to estimate the proportion of adults with multiple atopic diseases in the Dutch general population and evaluate the prevalence of limited health literacy, as well as its association with socioeconomic status, lifestyle factors, and health-related quality of life. The study found that 11.8% of the overall study population reported having multiple atopic diseases, and 23.6% of them had limited functional health literacy, with a higher prevalence among those with a low socioeconomic status.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Add to Collection

Letter Dermatology

Investigator Global Assessment for impetiginization in atopic dermatitis: development and initial reliability testing

Aviel Ragamin, Ron A. Tupker, Marlies de Graaf, Thomas Rustemeyer, Suzanne G. M. A. Pasmans, Renske Schappin, Marie L. A. Schuttelaar

Summary: This study developed and validated an Investigator Global Assessment (IGA) scale for evaluating the severity of impetiginization in patients with atopic dermatitis (AD).

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Hazard identification and the prevalence of occupational skin disease in Indonesian Batik workers

Sri Awalia Febriana, Yohanes Ridora, Niken Indrastuti, Kusuma Dewi, Katharina Oginawati, Ikeu Tanziha, Cita Rosita Sigit Prakoeswa, Fajar Waskito, Marie-Louise Schuttelaar

Summary: This study aimed to identify potential health hazards and investigate the prevalence of occupational skin diseases (OSD) in the traditional batik industry in Indonesia. The workers were exposed to substances that act as irritants and potential contact allergens during each step of the batik manufacturing process. The study found a high prevalence of OSD, especially contact dermatitis, among the employees.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Dermatology

Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis

Junfen Zhang, Laura Loman, Jantje M. Oldhoff, Marie L. A. Schuttelaar

Summary: This study found that there is a lack of knowledge about loneliness and psychiatric disorders other than anxiety and depression in patients with atopic dermatitis. It was revealed that atopic dermatitis is positively associated with chronic fatigue syndrome, burnout, depression, social phobia, panic disorder, attention deficit hyperactivity disorder, and eating disorder. Moreover, individuals with atopic dermatitis are more likely to experience loneliness. This study highlights the importance of recognizing and addressing the psychiatric and social aspects of atopic dermatitis.

ACTA DERMATO-VENEREOLOGICA (2023)

Add to Collection

Article Allergy

Transcriptional differences between vesicular hand eczema and atopic dermatitis

Fieke M. Rosenberg, Rene Wardenaar, Angelique N. Voorberg, Diana C. J. Spierings, Marie-Louise A. Schuttelaar

Summary: This study re-analyzed the transcriptome data of vesicular hand eczema (VHE) and atopic dermatitis (AD), and found that interferon signaling and necroptosis were significantly increased in VHE compared to AD, as well as some downregulated genes unique to VHE.

CONTACT DERMATITIS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.